In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...
NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...
Astronomy on MSN
Jan. 8, 1942: The birth of Stephen Hawking
Today in the history of astronomy, one of the brightest and most famous scientific minds of the modern era is born.
ALS is a rare and fatal disease that affects the nervous system, according to the Mayo Clinic. Also known as Lou Gehrig’s ...
Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several ...
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc.
QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...
ALS patients and their caregivers benefit most from flexible psychological support that combines emotional care, open ...
Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...
Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it ...
A New York law grants patients the right to request aid in dying. But do the clinicians who guide them through that decision ...
NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback